Metabolic effects combination glipizide human proinsulin treatment NIDDM effects mo treatment combination glipizide human proinsulin small group monitored patients patients non-insulin-dependent diabetes NIDDM poor glucose regulation maximal sulfonylurea therapy randomized double-blind placebo-controlled trial treatment groups mg glipizide min breakfast dinner human proinsulin bedtime glipizide human proinsulin placebo placebo human proinsulin Glycemic regulation measurements plasma glucose profiles hemoglobin observations combination glipizide human proinsulin effective agent overall glycemia patients NIDDM data support concept use agent day major effects agent bedtime hepatospecific 